Abbott Laboratories of Abbott Park, IL, has enrolled the first patient in a new clinical trial of the company's Xience V everolimus-eluting stent.
Abbott's Spirit Women trial is designed to understand how heart disease affects women and assess the performance of Xience V in women with previously untreated coronary lesions from Europe, Asia-Pacific, Canada, and Latin America. Dr. Liliana Grinfeld of the Hospital Italiano in Buenos Aires, Argentina, performed the first procedure in the trial.
By AuntMinnie.com staff writers
July 20, 2007
Related Reading
GE, Abbott break off acquisition, July 11, 2007
GE Healthcare to expand once more with $8 billion Abbott deal, January 19, 2007
GE announces Abbott diagnostics bid, January 18, 2007
Reports: GE to buy Abbott diagnostics units, January 18, 2007
Abbott touts stent results, October 25, 2006
Copyright © 2007 AuntMinnie.com
